'For quarter ending June 2024, consolidated Net sales (including other operating income) of Ajanta Pharma has increased 12.13% to Rs 1144.92 crore compared to quarter ended June 2023. Operating profit margin has jumped from 26.57% to 28.85%, leading to 21.76% rise in operating profit to Rs 330.35 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 21.22% to 20.54%. Purchase of finished goods cost rose from 3.86% to 3.90%. Employee cost increased from 20.77% to 24.45%. Other expenses fell from 27.72% to 22.65%.
Other income fell 16.63% to Rs 26.47 crore. PBIDT rose 17.74% to Rs 356.82 crore. Provision for interest fell 14.12% to Rs 0.73 crore.
PBDT rose 17.82% to Rs 356.09 crore. Provision for depreciation rose 2.38% to Rs 33.97 crore.
Profit before tax grew 19.73% to Rs 322.12 crore. Share of profi...
Pleaselogin & subscribe to view the full report.
More Reports
|
|